Valneva SE (VALN) Restructuring Costs (2023 - 2024)
Valneva SE's (VALN) quarterly Restructuring Costs came in at -$1.0 million in Q2 2024, up 91.56% quarter-over-quarter from -$12.0 million in Q4 2023.
Valneva SE (VALN) Restructuring Costs (2023 - 2024) Analysis & Trends
Valneva SE has disclosed Restructuring Costs across 2 years of filings, most recently posting -$1.0 million for Q2 2024.
- Restructuring Costs for Q2 2024 came in at -$1.0 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2024 was -$1.0 million (changed N/A YoY), and the FY2023 annual result was -$12.0 million, changed N/A from the prior year.
- Restructuring Costs came in at -$1.0 million for Q2 2024 at Valneva SE, up from -$12.0 million in the prior quarter.
- In the past five years, Restructuring Costs ranged from a high of -$1.0 million in Q2 2024 to a low of -$12.0 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - |
| 10 | Valneva SE | 167.33 Mn | 44.10 Mn | 5.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -1.02 Mn |
| Dec 31, 2023 | -12.05 Mn |